Company: CERO
Filing Date: 2025-01-07
Form Type: 424B3
Source: 0001213900-25-001658
Chunk: 7

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-07
Form: 424B3
Chunk 7
---
 |
| Common Stock, par value $0.0001 per share                              |     | CERO              |     | NASDAQ Global Market     |
| Warrants, each whole warrant exercisable for one share of common stock |     | CEROW             |     | NASDAQ Capital Market    |

Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On January 6, 2025, CERo
Therapeutics Holdings, Inc. (the “Company”) filed an amendment (the “Certificate of Amendment”) to its Second
Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time, to effectuate a reverse stock split of
the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”).

As previously disclosed,
at its Autumn 2024 Special Meeting of Stockholders held on November 11, 2024 (the “Special Meeting”), and upon the recommendation
of the Company’s Board of Directors (the “Board”), the Company’s stockholders approved a certificate of amendment
to effect a reverse stock split of the Common Stock at a ratio ranging from any whole number between 1-for-25 and 1-for-150, as determined
by the Board in its discretion, subject to the Board’s authority to abandon such amendment (the “Charter Amendment”).

The Charter Amendment was
described in detail under “Proposal No. 1: Reverse Stock Split Proposal” beginning on page 10 of the Company’s definitive
proxy statement filed with the Securities and Exchange Commission on October 15, 2024 (the “Proxy Statement”) in connection
with the Annual Meeting. The text of the Charter Amendment was included in Appendix A of the Proxy Statement.

On December 25, 2024, the
Board approved a reverse stock split of the Common Stock at a ratio of 1-for-100. Effective